Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Background: Anlotinib is a multi-target anti-angiogenic agent. The retrospective study was conducted to evaluate the safety and effectiveness of anlotinib as monotherapy or combination therapy for the treatment of recurrent high-grade gliomas. Methods: In this retrospective study, patients with recu...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | diagnostic images research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
7/6/2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |